Factors Associated With Breast Cancer Risks and Outcomes
The purpose of this study is to learn more about risks and outcomes of breast cancer in people with different backgrounds. Tissue and blood will be collected from participants for research purposes. Participants will complete questionnaires during their standard medical care. The study will not provide treatment for cancer or any other condition.
Conditions studied
Breast Cancer
About this study
The purpose of this study is to learn more about risks and outcomes of breast cancer in people with different backgrounds. Tissue and blood will be collected from participants for research purposes. Participants will complete questionnaires during their standard medical care. The study will not provide treatment for cancer or any other condition.
Interventions
- Other: Survey — Complete surveys: * Baseline (within 6 months of enrollment) * 1st follow-up survey (approx. 6 months to 12 months) * 2nd follow-up survey and/or blood collection (approx. 3 years +/- 6 months) * 3rd follow-up survey and/or blood collection (approx. 5 years +/- 6 months)
Primary outcomes
- Recurrence Free Survival/RFS (5 years)
Eligibility information
Study locations
- Memorial Sloan Kettering Cancer Center Basking Ridge (Limited Protocol Activities), Basking Ridge, New Jersey 07920 United States
- Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown, New Jersey 07748 United States
- Memorial Sloan Kettering Bergen (Limited Protocol Activities), Montvale, New Jersey 07645 United States
- Memorial Sloan Kettering Suffolk-Commack (Limited Protocol Activities), Commack, New York 11725 United States
- Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison, New York 10604 United States
- Memorial Sloan Kettering Cancer Center (All Protocol Activites), New York, New York 10065 United States
- Memorial Sloan Kettering Nassau (Limited Protocol Activites), Rockville Centre, New York 11553 United States
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.